Literature DB >> 16762541

Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis.

R Merola1, M Mottolese, G Orlandi, E Vico, F Cognetti, I Sperduti, A Fabi, G Vitelli, A M Cianciulli.   

Abstract

Our aim was to determine the aneusomy level and the HER-2 gene copy numbers, by fluorescence in situ hybridization (FISH) and to analyze their impact on the amplification rate in breast carcinomas considered HER-2 weakly positive cases by immunohistochemistry. We evaluated 343 breast carcinomas using double colour FISH (LSI Her-2/neu gene and CEP 17). Monosomy and polysomy were demonstrated in 24.2% and 46.1% respectively and 101/343 (29.6%) of the specimens were amplified by FISH. A statistically significant difference was observed, when we compared the amplification percentage in polysomic and monosomic specimens (P<0.0001) and, among polysomic specimens, when tumours were compared with HER-2 gene signals number per cell between 3 and 10 and >10 respectively (P<0.0001). Logistic regression analysis showed that HER-2 signals >10 and polysomy absence were independently associated with amplification. Our results confirm that the majority of 2+ IHC cases express the HER-2 protein without gene amplification and highlight the effect of chromosome 17 aneusomy and the HER-2 gene copy number on amplification.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16762541     DOI: 10.1016/j.ejca.2006.03.011

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  11 in total

1.  Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.

Authors:  Anna Zaczek; Aleksandra Markiewicz; Anna Supernat; Natalia Bednarz-Knoll; Burkhardt Brandt; Barbara Seroczyńska; Jarosław Skokowski; Jolanta Szade; Piotr Czapiewski; Wojciech Biernat; Marzena Wełnicka-Jaśkiewicz; Jacek Jassem
Journal:  Pathol Oncol Res       Date:  2012-03-18       Impact factor: 3.201

2.  Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.

Authors:  Kirsten Vang Nielsen; Bent Ejlertsen; Susanne Møller; Maj-Britt Jensen; Eva Balslev; Sven Müller; Ann Knoop; Henning T Mouridsen
Journal:  Mol Oncol       Date:  2011-11-26       Impact factor: 6.603

3.  Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series.

Authors:  Naoki Hayashi; Seigo Nakamura; Hiroshi Yagata; Yuji Shimoda; Hidekazu Ota; Gabriel N Hortobagyi; Massimo Cristofanilli; Naoto T Ueno
Journal:  Int J Clin Oncol       Date:  2011-01-06       Impact factor: 3.402

4.  HER2 status in breast cancer: experience of a Spanish National Reference Centre.

Authors:  Marta Cuadros; Carlos Cano; Francisco Javier López; Paloma Talavera; Inmaculada García-Peréz; Armando Blanco; Ángel Concha
Journal:  Clin Transl Oncol       Date:  2011-05       Impact factor: 3.405

5.  Comparison of fluorescence in situ hybridization and immunohistochemistry for assessment of HER-2 status in breast cancer patients.

Authors:  Lin Wang; Xiaobei Wang; Xiu Nie; Ling Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-06-10

6.  Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification.

Authors:  Matteo Brunelli; Alessia Nottegar; Giuseppe Bogina; Anna Caliò; Luca Cima; Albino Eccher; Caterina Vicentini; Lisa Marcolini; Aldo Scarpa; Serena Pedron; Eleonora Brunello; Sakari Knuutila; Anna Sapino; Caterina Marchiò; Emilio Bria; Annamaria Molino; Luisa Carbognin; Giampaolo Tortora; Bharat Jasani; Keith Miller; Ibrahim Merdol; Lucia Zanatta; Licia Laurino; Tiina Wirtanen; Giuseppe Zamboni; Marcella Marconi; Marco Chilosi; Erminia Manfrin; Guido Martignoni; Franco Bonetti
Journal:  Am J Cancer Res       Date:  2015-06-15       Impact factor: 6.166

Review 7.  Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response.

Authors:  Monica M Reinholz; Amy K Bruzek; Daniel W Visscher; Wilma L Lingle; Matthew J Schroeder; Edith A Perez; Robert B Jenkins
Journal:  Lancet Oncol       Date:  2009-03       Impact factor: 41.316

Review 8.  HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation.

Authors:  Soomin Ahn; Ji Won Woo; Kyoungyul Lee; So Yeon Park
Journal:  J Pathol Transl Med       Date:  2019-11-06

9.  The frequency and clinical significance of centromere enumeration probe 17 alterations in human epidermal growth factor receptor 2 immunohistochemistry-equivocal invasive breast cancer.

Authors:  Ayaka Katayama; Jane Starczynski; Michael S Toss; Abeer M Shaaban; Elena Provenzano; Cecily M Quinn; Grace Callagy; Colin A Purdie; Rebecca Millican-Slater; David Purnell; Leena Chagla; Tetsunari Oyama; Sarah E Pinder; Steve Chan; Ian Ellis; Andrew H S Lee; Emad A Rakha
Journal:  Histopathology       Date:  2022-08-08       Impact factor: 7.778

10.  HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients.

Authors:  Sasagu Kurozumi; Mary Padilla; Masafumi Kurosumi; Hiroshi Matsumoto; Kenichi Inoue; Jun Horiguchi; Izumi Takeyoshi; Tetsunari Oyama; Jim Ranger-Moore; D Craig Allred; Eslie Dennis; Hiroaki Nitta
Journal:  Breast Cancer Res Treat       Date:  2016-06-18       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.